Anti-tryptase treatment using nafamostat mesilate has a therapeutic effect on experimental colitis

Scandinavian Journal of Gastroenterology

Volumn 41, Issue 8, 2006, Pages 944-953

  Isozaki, Yutaka ^a   Yoshida, Norimasa ^a   Kuroda, Masaaki ^a   Handa, Osamu ^b   Takagi, Tomohisa ^b   Kokura, Satoshi ^b   Ichikawa, Hiroshi ^c   Naito, Yuji ^b   Okanoue, Takesi ^a   Yoshikawa, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY   (Japan)

Author keywords

Inflammatory bowel disease (IBD); Mast cell; Nafamostat mesilate (NM); Trinitrobenzene sulfonic acid (TNBS); Tryptase

Indexed keywords

ALCOHOL; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT 1; ENEMA; MESALAZINE; MYELOPEROXIDASE; NAFAMSTAT MESILATE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRINITROBENZENESULFONIC ACID; TRYPSIN INHIBITOR; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; COLITIS; COLON INJURY; COLON MUCOSA; CONTROLLED STUDY; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

AMINOSALICYLIC ACIDS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMOKINE CXCL1; CHEMOKINES, CXC; COLITIS; COLON; GUANIDINES; INTESTINAL MUCOSA; MALE; RATS; RATS, WISTAR; SERINE PROTEINASE INHIBITORS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TRINITROBENZENESULFONIC ACID; TRYPTASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745726787     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520500529470     Document Type: Article

References (37)

1. Raithel M, Winterkamp S, Pacurar A, Ulrich P, Hochberger J, Hahn EG. Release of mast cell tryptase from human colorectal mucosa in inflammatory bowel disease. Scand J Gastroenterol 2001;36:174-9.
2. Cenac N, Coelho AM, Nguyen C, Compton S, Patricia AG, Wallace K, et al. Induction of intestinal inflammation in mouse by proteinase-activated receptor-2. Am J Pathol 2002;161:1903-15.
3. Tremaine WJ, Brzezinski A, Katz JA, Wolf DC, Fleming TJ, Mordenti J, et al. Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment Parmacol Ther 2002;16:407-13.
4. Yamada T, Marshall S, Specian RD, Grisham MB. A comparative analysis of two models of colitis in rats. Gastroenterology 1992;102:1524-34.
5. Mori S, Itoh Y, Shinohata R, Sendo T, Oishi R, Nishibori M. Nafamostat mesilate is an extremely potent inhibitor of human tryptase. J Pharmacol Sci 2003;92:420-3.
6. Sendo T, Itoh Y, Goromaru T, Sumimura T, Saito M, Aki K, et al. A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium. Br J Pharmacol 2003;138:959-67.
7. Sendo T, Sumimura T, Itoh Y, Goromaru T, Aki K, Yano T, et al. Involvement of proteinase-activated receptor-2 in mast cell tryptase-induced barrier dysfunction in bovine aortic endothelial cells. Cell Signal 2003;15:773-81.
8. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989;96:795-803.
9. Guesdon JL, Ternynck T, Avrameas S. The use of avidin-biotin interaction in immunoenzymatic techniques. J Histochem Cytochem 1979;27:1131-9.
10. Walls AF, Jones DB, Williams JH, Church MK, Holgate ST. Immunohistochemical identification of mast cells in formaldehyde-fixed tissue using monoclonal antibodies specific for tryptase. J Pathol 1990;162:119-26.
11. Kojima R, Hamamoto S, Moriwaki M, Iwadate K, Ohwaki T. The new experimental ulcerative colitis model in rats induced by subserosal injection of acetic acid. Folia Pharmacol Jpn 2001;118:123-30.
12. Yoshida N, Yoshikawa T, Yamaguchi T, Naito Y, Tanigawa T, Murase H, et al. A novel water-soluble vitamin E derivative protects against experimental colitis in rats. Antioxid Redox Signal 1999;1:555-62.
13. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.
14. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology 1984;87:1344-50.
15. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-75.
16. Naito Y, Takagi T, Matsuyama K, Yoshida N, Yoshikawa T. Pioglitazone, a specific PPAR-γ ligand, inhibits aspirin-induced gastric mucosal injury in rats. Aliment Pharmacol Ther 2001;15:865-73.
17. Tomatsuri N, Yoshida N, Takagi T, Katada K, Isozaki Y, Imamoto E, et al. Edaravone, a newly developed radical scavenger, protects against ischemia-reperfusion injury of the small intestine in rats. Int J Mol Med 2004;13:105-9.
18. Bischoff SC, Lorentz A, Schwengberg S, Weier G, Raab R, Manns MP. Mast cells are an important cellular source of tumour necrosis factor α in human intestinal tissue. Gut 1999;44:643-52.
19. Fox CC, Lazenby AJ, Moore WC, Yardley JH, Bayless TM, Lichtenstein LM. Enhancement of human intestinal mast cell mediator release in active ulcerative colitis. Gastroenterology 1990;99:119-24.
20. Gelbmann CM, Mestermann S, Gross V, Köllinger M, Schölmerich J, Falk W. Strictures in Crohn's disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin. Gut 1999;45:210-7.
21. Xu X, Weksler-Zangen S, Pikarsky A, Pappo O, Wengrower D, Bischoff SC, et al. Mast cells involvement in the inflammation and fibrosis development of the TNBS induced rat model of colitis. Scand J Gastroenterol 2002;37:330-7.
22. Tsune I, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Takei Y, et al. Dietary glycine prevents chemical-induced experimental colitis in the rat. Gastroenterology 2003;125:775-85.
23. Stein J, Ries J, Barrett KE. Disruption of intestinal barrier function associated with experimental colitis: possible role of mast cells. Am J Physiol 1998;274:G203-9.
24. Stenton GR, Vliagoftis H, Befus AD. Role of intestinal mast cells in modulating gastrointestinal pathophysiology. Ann Alllergy Asthma Immunol 1998;81:1-15.
25. Aoyama T, Ino Y, Ozeki M, Oda M, Sato T, Koshiyama Y, et al. Pharmacological studies of FUT-175, nafamstat mesilate I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol 1984;35:203-27.
26. Temkin V, Kantor B, Weg V, Hartman ML, Schaffer FL. Tryptase activates the mitogen-activated protein kinase/activator protein-1 pathway in human peripheral blood eosinophils, causing cytokine production and release. J Immunol 2002;169:2662-9.
27. O'Brien PJ, Molino M, Kahn M, Brass LF. Protease activated receptors: theme and variations. Oncogene 2001;20:1570-81.
28. Corvera CU, Déry K, McConalogue K, Gamp P, Thoma M, Al-Ani B, et al. Thrombin and mast cell tryptase regulate guinea-pig myenteric neurons through proteinase-activated receptors-1 and -2. J Physiol 1999;517:741-56.
29. Shpacovitch VM, Brzoska T, Buddenkotte J, Stroh C, Sommerhoff CP, Ansel JC, et al. Agonists of proteinase-activated receptor 2 induce cytokine release and activation of nuclear transcription factor kappa B in human dermal microvascular endothelial cells. J Invest Dermatol 2002;118:380-5.
30. Kim JA, Choi SC, Yun KJ, Kim DK, Han MK, Seo GS, et al. Expression of protease-activated receptor 2 in ulcerative colitis. Inflamm Bowel Dis 2003;9:224-9.
31. Harada K, Toyonaga A, Mitsuyama K, Sasaki E, Tanikawa K. Role of cytokine-induced neutrophil chemoattractant, a member of the interleukin-8 family, in rat experimental colitis. Digestion 1994;55:179-84.
32. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344-67.
33. Yoshida N, Yamaguchi T, Kitazumi S, Takahasi S, Naito Y, Yoshikawa T, et al. Role of PMN and active oxygen species in the pathogenesis of TNBS-colitis in rats. In: Keusch GT, Kawakami M, editors. Cytokines, cholera, and the gut. Tokyo, Japan: IOS Press Ohmsha; 1995. pp 131-5.
34. Segars LW, Gales BJ. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease. Clin Pharmacol 1992;11:514-28.
35. Peterson TC, Cleary CE, Shaw AM, Malatjalian DA, Veldhuyzen van Zanten SJ. Therapeutic role for bismuth compounds in TNBS-induced colitis in the rats. Dig Dis Sci 2000;45:466-73.
36. Wallace JL, Macnaughton WK, Morris GP, Beck PL. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 1989;96:29-36.
37. Kennedy M, Wilson L, Szabó C, Salzman AL. 5-aminosalicylic acid inhibits iNOS transcription in human intestinal epithelial cells. Int J Mol Med 1999;4:437-43.